Forgot your account information?  |  Create a CME account

Edmonton firm locks down rights to oat-based chemical

Published by Steve Coleman on May 08, 2012

An Edmonton company has signed a global licensing agreement with Agriculture and Agri-Food Canada for a product it says has strong potential in the food, nutraceutical and pharmaceutical fields.

Ceapro has acquired exclusive rights for all fields of use for an avananthramide process technology.

The process substantially increases the amount of the substance manufacturing can extract from oats. The chemical normally only appears in small amounts.

"Our core value driver is avenanthramides and this new technology licensed from the Canadian Government will be a game changer for Ceapro," said Mr. Gilles Gagnon, acting CEO, in a news release. "In addition to the cosmetics market, this new technology should allow Ceapro to develop large quantities of new products from avenanthramides with potential applications in functional food, nutraceutical, and pharmaceutical areas, which represent very large potential markets."

In terms of medical applications, avananthramide has potential treating metabolic diseases, atherosclerosis, inflammatory bowel syndrome, colon cancer and exercise induced inflammation. The chemical was first discovered 25 years ago.

Found in: news

National Office

Alberta British Columbia
Manitoba New Brunswick
Newfoundland & Labrador Nova Scotia
Ontario Québec
Prince Edward Island Saskatchewan